-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Most patients with gastrointestinal stromal tumors (GIST) carry activating mutations in the KIT/PDGFRA gene and initially respond to tyrosine kinase inhibitor (TKI) treatment
.
The acquisition of secondary mutations leads to refractory/relapsed disease
Gastrointestinal stromal tumor
In this study, the researchers collected tumor tissue and liquid biopsy samples from the tested patients, extracted circulating tumor DNA, and performed second-generation sequencing
.
This article aims to analyze the correlation between the KIT/PDGFRA mutation status and the clinical outcome of patients
Mutation detection status
In total, a total of 129 patients were recruited (85 taking reptinib 150 mg/day; 44 taking placebo)
.
The most common primary mutations detected in the combination of tumor tissue and liquid biopsy samples are located in KIT exon 11 (61.
The most common primary mutations detected in combination of tumor tissue and liquid biopsy samples are located in exon 11 of KIT.
Progression-free survival of two groups of patients stratified according to mutation status
Regardless of the mutation status of the tested patients, the progression-free survival (PFS) benefit of patients receiving repatinib was better than that of the placebo group (HR 0.
16; exon 11 mutation p<0.
0001, exon 9 Mutation p=0.
0023, exon 13 mutation p<0.
0001, exon 17 mutation p<0.
0001)
.
In patients without KIT/PDGFRA mutations (wild-type), the PFS of patients in the repatinib group and placebo group fluctuated between 2-23 months and 0.
The progression-free survival (PFS) benefits of patients receiving repatinib were better than those of the placebo group .
Reptinib provides clinically significant therapeutic activity in the mutation subgroup of patients with advanced GIST, demonstrating that reptinib can inhibit advanced GIST with a wide range of KIT/PDGFRA mutations that have previously received three or more TKI treatments The patient reptinib provides clinically significant therapeutic activity in the mutation subgroup of patients with advanced GIST, which proves that reptinib can inhibit the advanced stage that has received three or more TKI treatments with a wide range of KIT/PDGFRA mutations.
Original source:
Sebastian Bauer, et al.
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT / PDGFRA Mutations in the Phase III INVICTUS Study in this message
